AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3018363 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (Group II)
Number of subjects: 30
Study 3018363 — intervention group
Group type: COMPARATOR
Intervention: Control (Group I)
Number of subjects: 30
Study 30175329 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus omega-3 fatty acids supplementation
Number of subjects: 50
Study 30175329 — intervention group
Group type: COMPARATOR
Intervention: SRP alone (control group)
Number of subjects: 50
Study 26656289 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 100
Study 26656289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24376099 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 40mg/day, titrated to a maximum of 120mg/day
Number of subjects: 233
Study 22267751 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (up to 300 mg daily)
Number of subjects: 3605
Study 22267751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3605
Study 20363812 — intervention group
Group type: EXPERIMENTAL
Intervention: Rear-view camera and sensor system-based parking aid
Number of subjects: 46
Study 20363812 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rear-view camera and sensor system)
Number of subjects: 46
Study 18547413 — intervention group
Group type: EXPERIMENTAL
Intervention: Childbirth classes for public health nurses (PHN)
Number of subjects: 1601
Study 18547413 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1601
Study 16902231 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion control shoes (New Balance 1122)
Number of subjects: 40
Study 16902231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushion trainer shoes (New Balance 1022)
Number of subjects: 40
Study 12492668 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 60
Study 12492668 — intervention group
Group type: COMPARATOR
Intervention: PAXpress
Number of subjects: 60
Study 11121979 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofiltration (BF)
Number of subjects: 5
Study 11121979 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate hemodialysis (BcHD)
Number of subjects: 5
Study 8730004 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose theophylline
Number of subjects: 17
Study 1686746 — intervention group
Group type: EXPERIMENTAL
Intervention: dilevalol (200 mg, 400 mg or 600 mg)
Number of subjects: 28
Study 1686746 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 28
Study 6134547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular papaveretum
Number of subjects: 100
Study 6134547 — intervention group
Group type: COMPARATOR
Intervention: Oral temazepam
Number of subjects: 100
Study 31774519 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group
Number of subjects: 448
Study 31774519 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group
Number of subjects: 448
Study 31774519 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group (nonmetropolitan)
Number of subjects: 448
Study 31774519 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (nonmetropolitan)
Number of subjects: 448
Study 31774519 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group (missing teeth)
Number of subjects: 448
Study 31774519 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (missing teeth)
Number of subjects: 448
Study 31774519 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group (percentage of missing teeth > 0)
Number of subjects: 448
Study 31774519 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (percentage of missing teeth > 0)
Number of subjects: 448
Study 29952047 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive (SE) group intervention
Number of subjects: 161
Study 29952047 — intervention group
Group type: COMPARATOR
Intervention: Standard risk-counseling (RC)
Number of subjects: 161
Study 25959424 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Voice Rehabilitation Program (CVRP)
Number of subjects: 80
Study 25959424 — intervention group
Group type: COMPARATOR
Intervention: Vocal Function Exercises (VFE)
Number of subjects: 80
Study 24457315 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy with helical tomotherapy (HT‐SBRT)
Number of subjects: 30
Study 22752859 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 0
Study 21036667 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Number of subjects: 64
Study 21036667 — intervention group
Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 64
Study 17616473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous valproate (IV VA)
Number of subjects: 100
Study 17616473 — intervention group
Group type: COMPARATOR
Intervention: Intravenous phenytoin (IV phenytoin)
Number of subjects: 100
Study 15923119 — intervention group
Group type: EXPERIMENTAL
Intervention: Supra-aortic gastro-esophageal anastomosis
Number of subjects: 60
Study 15923119 — intervention group
Group type: COMPARATOR
Intervention: Sub-aortic gastro-esophageal anastomosis
Number of subjects: 60
Study 12418118 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 147
Study 12418118 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40-80 mg
Number of subjects: 147
Study 12418118 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine 20 mg
Number of subjects: 147
Study 12418118 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Propranolol 40 mg and Trimetazidine 20 mg
Number of subjects: 147
Study 12418118 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 120 mg/day
Number of subjects: 147
Study 12418118 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine 60 mg/day
Number of subjects: 147
Study 12418118 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Propranolol 120 mg/day and Trimetazidine 60 mg/day
Number of subjects: 147
Study 12418118 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 147
Study 12418118 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of Propranolol and Trimetazidine
Number of subjects: 147
Study 10613408 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol ester (3 grams daily from three servings of spread containing one gram of plant stanols each)
Number of subjects: 0
Study 10613408 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran fiber (5 grams for the first two weeks, then 10 grams for the second two weeks)
Number of subjects: 0
Study 8564625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitolterol mesylate metered-dose inhaler (1, 2, or 3 inhalations)
Number of subjects: 46
Study 8564625 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double-blind, randomized)
Number of subjects: 46
Study 1834587 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil diet (N-3 fatty acids)
Number of subjects: 12
Study 6749458 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous branched-chain amino acid solutions in 20% glucose (group A)
Number of subjects: 40
Study 6749458 — intervention group
Group type: COMPARATOR
Intervention: Lactulose plus glucose in isocaloric amount (group B)
Number of subjects: 40
Study 31669427 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine blood parameters (platelet count, CRP levels, GMI) during antifungal treatment
Number of subjects: 374
Study 31669427 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count increase
Number of subjects: 374
Study 31669427 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP drop
Number of subjects: 374
Study 31669427 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count increase in CAS cohort
Number of subjects: 374
Study 31669427 — intervention group
Group type: EXPERIMENTAL
Intervention: GMI drop
Number of subjects: 374
Study 31669427 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis for survival
Number of subjects: 374
Study 31669427 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline platelet count
Number of subjects: 374
Study 29880220 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress immediately before learning
Number of subjects: 0
Study 29880220 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress 30 minutes before learning
Number of subjects: 0
Study 29880220 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress (timing independent) in non-carriers of the BclI polymorphism
Number of subjects: 0
Study 29880220 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress (timing independent) in carriers of the BclI polymorphism
Number of subjects: 0
Study 29061616 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT‐TLIF
Number of subjects: 254
Study 29061616 — intervention group
Group type: COMPARATOR
Intervention: PS‐TLIF
Number of subjects: 254
Study 25725903 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week exercise program with elastic bands, twice a week
Number of subjects: 51
Study 25725903 — intervention group
Group type: COMPARATOR
Intervention: Walking programme (control)
Number of subjects: 51
Study 24297587 — intervention group
Group type: EXPERIMENTAL
Intervention: Early post-surgical radiation therapy (within 3 months)
Number of subjects: 95
Study 24297587 — intervention group
Group type: COMPARATOR
Intervention: Late post-surgical radiation therapy (at disease progression)
Number of subjects: 95
Study 21098003 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (Bicarb, 1 M; 350‐500 ml)
Number of subjects: 6
Study 21098003 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Sal)
Number of subjects: 6
Study 21098003 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (Bicarb)
Number of subjects: 6
Study 19179918 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS
Number of subjects: 102
Study 19179918 — intervention group
Group type: COMPARATOR
Intervention: ICBG
Number of subjects: 102
Study 17317757 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane combined with dolasetron (SD)
Number of subjects: 126
Study 17317757 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based total intravenous anaesthesia (TIVA)
Number of subjects: 126
Study 17317757 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TIVA and dolasetron prophylaxis
Number of subjects: 126
Study 17317757 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of anaesthetic (TIVA vs SD)
Number of subjects: 126
Study 15383105 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurokinin B plasma levels in pre-eclamptic patients
Number of subjects: 90
Study 15383105 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurokinin B plasma levels in IUGR patients
Number of subjects: 90
Study 15383105 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide metabolites levels in pre-eclamptic patients
Number of subjects: 90
Study 15383105 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide metabolites levels in IUGR patients
Number of subjects: 90
Study 15383105 — intervention group
Group type: COMPARATOR
Intervention: Correlation between neurokinin B plasma values and nitric oxide metabolite levels in pre-eclampsia
Number of subjects: 90
Study 15383105 — intervention group
Group type: COMPARATOR
Intervention: Correlation between neurokinin B plasma values and nitric oxide metabolite levels in IUGR
Number of subjects: 90
Study 15383105 — intervention group
Group type: COMPARATOR
Intervention: Correlation between neurokinin B plasma values and nitric oxide metabolite levels in controls
Number of subjects: 90
Study 11291422 — intervention group
Group type: EXPERIMENTAL
Intervention: Whistle Watch (WW) device
Number of subjects: 80
Study 11291422 — intervention group
Group type: COMPARATOR
Intervention: Patient's perceived symptomatology
Number of subjects: 80
Study 9433615 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected third-degree relatives method (cousins method - CM)
Number of subjects: 0
Study 9433615 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated extended family data set
Number of subjects: 0
Study 8239161 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms 3 times/day) continued for 6 months
Number of subjects: 28
Study 8239161 — intervention group
Group type: COMPARATOR
Intervention: Budesonide tapering-off (decrease dose within 2 months, followed by placebo for 4 months)
Number of subjects: 28
Study 3159162 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole 2% + benzoyl peroxide 5% (Acnidazil) applied twice a day
Number of subjects: 60
Study 3159162 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide 5%
Number of subjects: 60
Study 30352035 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (IAYT training for 14 weeks, 1.5 hours daily for 5 days a week)
Number of subjects: 72
Study 30352035 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yoga activity, only walking)
Number of subjects: 72
Study 27829371 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation therapy
Number of subjects: 0
Study 24867391 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (12 mg/day or individual maximum tolerated dose)
Number of subjects: 1216
Study 23528509 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based interventions for unintentional injury prevention
Number of subjects: 234
Study 23528509 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based interventions for smoking cessation
Number of subjects: 234
Study 23528509 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based interventions for risky behaviors
Number of subjects: 234
Study 23528509 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based interventions for various risky behaviors
Number of subjects: 234
Study 20373477 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine, Olanzapine, Haloperidol, Risperidone (antipsychotics)
Number of subjects: 154
Study 18958158 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry faces
Number of subjects: 0
Study 18958158 — intervention group
Group type: COMPARATOR
Intervention: Happy faces
Number of subjects: 0
Study 18958158 — intervention group
Group type: COMPARATOR
Intervention: Neutral faces
Number of subjects: 0
Study 16882633 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex training (dynamic constant external resistance and plyometrics), performed three times a week for 12 weeks.
Number of subjects: 54
Study 16882633 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 54
Study 12795581 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 244
Study 12795581 — intervention group
Group type: COMPARATOR
Intervention: Self-study condition
Number of subjects: 244
Study 10958716 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg sildenafil
Number of subjects: 15
Study 10958716 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 15
Study 10958716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8712189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 190
Study 8712189 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 190
Study 1282465 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg kg‐1 h‐1)
Number of subjects: 0
Study 1282465 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (5 micrograms kg‐1 h‐1)
Number of subjects: 0
Study 1282465 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK8 (graded doses)
Number of subjects: 0
Study 1282465 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 0
Study 6771979 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined film-screen/xeromammography
Number of subjects: 53
Study 6771979 — intervention group
Group type: COMPARATOR
Intervention: Mediolateral noncontact xeromammogram
Number of subjects: 53
Study 6771979 — intervention group
Group type: COMPARATOR
Intervention: Mediolateral and craniocaudal film-screen mammograms
Number of subjects: 53
Study 6771979 — intervention group
Group type: COMPARATOR
Intervention: Xeromammography
Number of subjects: 53
Study 6771979 — intervention group
Group type: COMPARATOR
Intervention: Film-screen mammography
Number of subjects: 53
Study 30466808 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medications (antidepressants and anxiolytics)
Number of subjects: 719
Study 30466808 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (pre-existing prescriptions)
Number of subjects: 719
Study 30466808 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (new prescriptions perioperatively)
Number of subjects: 719
Study 30466808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic and clinical characteristics
Number of subjects: 719
Study 29026292 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic health group intervention (10 sessions, 90 minutes each, once per week)
Number of subjects: 38
Study 29026292 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardized basic educational materials)
Number of subjects: 38
Study 29026292 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic health group intervention
Number of subjects: 38
Study 26481873 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention (remote monitoring/management of chemotherapy side-effects) in addition to 'Usual Care'.
Number of subjects: 222
Study 26481873 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (control group).
Number of subjects: 222
Study 23324454 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-balloon dilation (LBD) alone
Number of subjects: 131
Study 23324454 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy (EST) plus large-balloon dilation (LBD)
Number of subjects: 131
Study 21248294 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with insulin resistance (IR)
Number of subjects: 2418
Study 21248294 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals without CKD
Number of subjects: 2418
Study 21248294 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with CKD
Number of subjects: 2418
Study 21248294 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 2418
Study 19582244 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamucobase
Number of subjects: 53
Study 19582244 — intervention group
Group type: COMPARATOR
Intervention: Kenalog in Orabase
Number of subjects: 53
Study 17694693 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education for children alone
Number of subjects: 245
Study 17694693 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education for both children and caregivers
Number of subjects: 245
Study 17694693 — intervention group
Group type: COMPARATOR
Intervention: Group education for caregivers alone
Number of subjects: 245
Study 17694693 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 245
Study 17190936 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol gel
Number of subjects: 35
Study 17190936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 12691336 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise twice a week
Number of subjects: 231
Study 12691336 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar lifting test
Number of subjects: 231
Study 12691336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical lifting test
Number of subjects: 231
Study 12691336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical lifting test and gait test with burden
Number of subjects: 231
Study 12691336 — intervention group
Group type: COMPARATOR
Intervention: High-rated pain behaviour and perceived high pain intensity
Number of subjects: 231
Study 10608530 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular control
Number of subjects: 56
Study 10608530 — intervention group
Group type: COMPARATOR
Intervention: No vascular control
Number of subjects: 56
Study 7862216 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 135 mg/m2
Number of subjects: 55
Study 7862216 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2
Number of subjects: 55
Study 7862216 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (both dosages)
Number of subjects: 55
Study 2287558 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 350
Study 2287558 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg
Number of subjects: 350
Study 2287558 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 65 mg
Number of subjects: 350
Study 2287558 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg + Caffeine 65 mg
Number of subjects: 350
Study 2287558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 6117516 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 6117516 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepindolol
Number of subjects: 0
Study 6117516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6117516 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (controls)
Number of subjects: 0
Study 6117516 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade (hypertensives)
Number of subjects: 0
Study 29442087 — intervention group
Group type: EXPERIMENTAL
Intervention: Profluorid Varnish (Voco: Cuxhaven Germany)
Number of subjects: 28
Study 29442087 — intervention group
Group type: EXPERIMENTAL
Intervention: Admira Protect (Voco: Cuxhaven Germany)
Number of subjects: 28
Study 29442087 — intervention group
Group type: EXPERIMENTAL
Intervention: PRG‐Barrier Coat (Shofu: Japan)
Number of subjects: 28
Study 26647424 — intervention group
Group type: COMPARATOR
Intervention: Cinacalcet
Number of subjects: 30
Study 26647424 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal parathyroidectomy
Number of subjects: 30
Study 25701373 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo low-dose tacrolimus/sirolimus (lowTAC/SIR)
Number of subjects: 126
Study 25701373 — intervention group
Group type: COMPARATOR
Intervention: Full-dose tacrolimus/mycophenolate mofetil (TAC/MMF)
Number of subjects: 126